

Q4 1. (Amended) A diagnostic agent for a disease caused by the tumorigenic change of a hematopoietic cell, comprising an anti-human VEGF receptor Flt-1 antibody as an active ingredient.

Q5 7. (Amended) A therapeutic agent for a disease caused by the tumorigenic change of a hematopoietic cell, comprising an anti-human VEGF receptor Flt-1 antibody as an active ingredient.

Q6 13. (Amended) A method for diagnosing a disease caused by the tumorigenic change of a hematopoietic cell, comprising reacting cells or tissues of a person with an anti-human VEGF receptor Flt-1 antibody to immunologically detect or determine a human VEGF receptor Flt-1 existing in the cells or tissues.

14. (Amended) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

15. (Amended) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750. SP

16. (Amended) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

17. (Amended) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', F(ab')₂, a single chain antibody and a disulfide stabilized antibody.

18. (Amended) The method according to claim 13, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.

Please add the following new claims.

19. (New) The diagnostic agent according to claim 1, wherein the disease is leukemia.

20. (New) The therapeutic agent according to claim 7, wherein the disease is leukemia.

21. (New) The method according to claim 13, wherein the disease is leukemia.

22. (New) A method for treating a disease caused by the tumorigenic change of a hematopoietic cell, comprising administering to a patient in need thereof an effective amount of an anti-human VEGF receptor Flt-1.

23. (New) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is a monoclonal antibody.

24. (New) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of KM1730, KM1731, KM1732, KM1748 and KM1750.

25. (New) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is a humanized antibody.

26. (New) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody selected from the group consisting of Fab, Fab', F(ab')₂, a single chain antibody and a disulfide stabilized antibody.

27. (New) The method according to claim 22, wherein the anti-human VEGF receptor Flt-1 antibody is an antibody fused with a radioisotope, a protein or a low molecular weight agent by a chemical or genetic engineering means.